DELIC is positioned as an early leader in a huge $70 billion market with enormous unmet demand.
2
DELIC founders are following the proven billion-dollar business model they helped create to drive enormous value in the cannabis market. With management’s previous time spent at High Times, the largest cannabis publication in the world founded in 1974, this comes with an enormous connected network. This value-add for shareholders entering the psychedelics sector cannot go unnoticed.
3
DELIC recently acquired Ketamine Infusion Centers LLC (KIC) with operations in both California and Arizona. Over the past 3 years, KIC has overseen 4,000 treatments and is profitable! This is a potential game changer to not only increase much-needed mental health solutions to a wider audience both young and old, but at the same time, increase immediate growth by expanding their clinic roll-out across America.
4
An innovative focus on science and IP related to psilocybin gives DELIC a potential multi-year head start. The company recently acquired Complex Biotech Discovery Ventures (CBDV), a licensed profitable psilocybin and cannabis research laboratory with existing blue chip clients. DELIC benefits from CBDV’s current revenue as well as now having a scientific team to build and commercialize psilocybin-related intellectual property for solutions associated with PTSD, anxiety, stress disorders, depression, alcoholism, and multiple other mental health issues. This is absolutely enormous!
5
The company has low start-up and operating costs, targeting strong profit margins, unlike competitors that require millions of dollars and several years to bring products to market. DELIC through a smart acquisition strategy is making this a reality now for investors.
6
DELIC is positioned to have first mover advantage and capture a market segment that has no dominant players yet.
7
Next to Compass Pathways, DELIC is one of the very rare psychedelics companies with support from big name billion-dollar value creators who are either on the board of directors or serve in an advisory capacity. These heavy backers are proven value creators!
[custom_player id=rRbrU2tpTHE]
1
Mental disorders have risen to rank among the most devastating and costly medical challenges in the United States and the world. Estimates are that 300 million people globally suffer the debilitating effects of PTSD, chronic depression/anxiety, and the related impact of opioid addictions.
2
Clinical trials have already shown significant promise for treating these disorders with cannabinoids and psychedelic compounds. Until recently these compounds have been vilified as illegal recreational drugs. Now, clinicians and medical researchers are unlocking a vast array of therapeutic potentials for treating some of the most challenging medical issues. Allied is contributing to this research with its own clinical trials treating PTSD, depression/anxiety disorders and opioid addiction.
3
On the heels of new therapeutic breakthroughs, the FDA is now fast-tracking approval processes for the psychedelic compound psilocybin. This fast-track approval process could lead to therapeutic approvals this year, which can be added to already advanced treatments being evaluated for cannabinoid compounds. Investors are moving aggressively in anticipation of a stream of approvals that could begin as early as this year.
4
Though this market remains in its infancy, early gainers have posted ten- to thirty-times growth from this emerging trend. This is a rapidly growing, multi-billion-dollar market in the making — one of the very few that you will see in your lifetime.
5
Allied Corp. (OTCQB: ALID) is unique in the world in that it has focused diligently on building the end-to-end capability to deliver pharmaceutical-grade cannabinoids and psychedelic compounds (as legislation allows) at a scale that meets all current global growth projections. The company is now fully structured to become one of the largest, if not the largest, supplier of pharmaceutical-grade cannabinoids and psychedelic compounds to the world. Its capabilities allow total control, end to end, of the supply chain. Nobody else does what they do to provide scalable, high-quality, and dependable compounds to a market projected to approach $60 billion this decade!
Draganfly Vital Intelligence Technology Reducing the Spread of COVID-19 in Schools
1
The United States (and the world) cannot withstand ongoing lockdowns due to the COVID-19 pandemic...nor any potential future public health crisis. People could be allowed to return to work, school, and other venues by installing Draganfly's Vital Intelligence technology.
2
The world drone market (Draganfly's core business) is taking off at a breathtaking pace. The annual market size is projected to leap from $23 billion last year to an astonishing $145 billion by 2025.
3
Much of the domestic market for drones has been entirely disrupted by the Pentagon’s decision to ban the use of Chinese-made drone technology — a decision that has since extended into other branches of government across the board. As deployment of small drone technologies expands in the military, homeland security and public safety sectors, high priority for future contracts will be given to North American companies. This seriously cannot be understated!
4
Draganfly is the oldest and one of the most experienced North American commercial drone design and airborne technology manufacturers operating in the world today. Now that the company is publicly traded, any potential shareholder interest could be securing a ground-floor position in a company that, in my opinion, seems destined for explosive growth, in a market that is projected to soar over 10-fold in the coming five years. Now is the ideal time to begin your research and consider getting on board!
5
While Draganfly started as a drone company, it has advanced into a multi-faceted technology powerhouse adopting new technologies while advancing into other verticals such as health monitoring and robotics to capitalize on emerging market opportunities.
Draganfly (CSE: DFLY / OTCQB: DFLYF / FSE: 3U8), New Era in Aviation Seeing Unprecedented Growth
Three Powerful Reasons to Act on Draganfly
1
The world market for drone technology is taking off at a breathtaking pace. Annual market size is projected to leap from $23 billion last year to an astonishing $145 billion by 2025. Draganfly is becoming a key player in the domestic North American market, and is now positioned to grow aggressively in this expanding arena.
2
Much of the domestic market for drones has been entirely disrupted by the Pentagon’s decision to ban the use of Chinese-made drone technology — a decision that has since extended into other branches of government across the board. As deployment of small drone technologies expands in the military, homeland security and public safety sectors, high priority for future contracts will be given to North American companies. This seriously cannot be understated!
3
Draganfly is the oldest and one of the most experienced North American commercial drone design and manufacturing companies operating in the world today. Now that the company is publicly traded, any potential shareholder interest could be securing a ground-floor position in a company that, in my opinion, seems destined for explosive growth, in a market that is projected to soar over 10-fold in the coming six years. Now is the ideal time to begin your research and consider getting on board!
Koios Beverage: Nootropics Go Mainstream in a Delicious Beverage Line
Five Key Reasons to Consider Koios for Immediate Action
1
The energy drink category has become an at-risk consumer product category that is ripe for disruption. Koios is in a prime position with a next-generation product to displace leading energy drink brands like Monster, Red Bull and NOS.
2
Americans have always pursued products that gives them an edge, which was the driving force behind the growth of energy drinks and the stimulating effects that propelled energy drinks to a $16 billion market size. Koios products give users the effects that they desire from traditional energy drinks, but with none of the disadvantages. This is a smarter decision for consumers once educated!
3
Demand for nootropic natural brain boosters is now going mainstream across all segments (college students, members of the workforce, parents, etc.) of America. Koios is making a name for itself by using healthful ingredients and offering enjoyable flavors that will further drive brand loyalty to the company’s product offerings.
4
GNC, Walmart, and Amazon open the door to expand distribution of Koios to all consumer categories, young and old. This positions Koios beverages on hyper premium retail shelf space among America’s most iconic beverage brands.
5
Here’s the big one for investors: Big beverage companies have a long history of acquiring “rising star” brands that carve out new market segments or threaten old ones. Koios does both, as its products improve on benefits already in demand, and threaten the established, yet vulnerable market in energy drinks. Koios’ penetration has the potential to deliver value to shareholders.
3 Unstoppable Forces That Will Drive the Next Marijuana Super-Cycle
Top Five Reasons to Consider Sproutly Today
1
Disruptive Technology - The world’s first truly natural water-soluble cannabis solution for the beverage and edibles market. Solving the world’s solubility issues places the company ahead of the pack, potentially redefining the cannabis industry.
2
Superior Products - Sproutly is focused on delivering to market the highest quality beverage and edible products with strain-specific benefits. Onset of effects within 5 mins and offset of effects within 90 min solves the onset/offset challenge for the beverage industry. Both its water soluble Infuz2O and Bio Natural Oil (BNO) can be extracted from specific strains and lay the foundation for future consumer products and needs.
3
Licensed Producer - The company’s state-of-the-art facility is strategically located in the Greater Toronto Area, and will not only provide cultivation of dried cannabis flower… the facility will also be the initial extraction facility for its APP technology, with processing capacity of up to 10,000kg annually (100 million X 10mg doses of Infuz2O).
4
Experienced Management - Sproutly’s executive management team provides decades of experience in biopharmaceutical research & development, technology commercialization, and consumer beverage & packaged goods.
5
Huge Market Opportunity - The total North America market, including U.S.A. legalized states, is expected to approach $50 billion over the next five to seven years. The joint venture with Moosehead Breweries gives Sproutly an immediate and well-established route to Canadian and worldwide markets. Sproutly Canada Inc. has the potential to offer smart investors exposure to an explosive growth market.
Sproutly (OTCQB: SRUTF, CSE: SPR, FRA: 38G)
CEO Keith Dolo Discusses Sproutly’s Value Proposition With Respect to Legal Cannabis, and the Company’s Unique Advantage in the Beverage and Edibles Category[apss_share]
